{"database": "lobbying", "table": "lobbying_activities", "rows": [[1445165, "3b3d64e7-7e64-40cc-afcd-e78794345f22", "Q3", "KNIGHT CAPITOL CONSULTANTS", 40036301, "GENZYME CORPORATION", 2013, "third_quarter", "HCR", "Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board.  General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2013-10-16T19:33:34.300000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1445165"], "units": {}, "query_ms": 0.3891759552061558, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}